Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTRAY EXTENSION: Open-label Extension Study of Sotatercept in Pulmonary Arterial Hypertension
2024-518687-12-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 2, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Primary endpoints: Number of participants with one or more adverse events and Number of participants who discontinue study intervention due to an adverse event. Planned start Jun 2025; status: authorised.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2024-518687-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518687-12-00.